Will interferon-free regimens prevail?

Gastroenterology

Volumn 142, Issue 6, 2012, Pages 1351-1355

  Welsch, Christoph ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

CHC; chronic hepatitis C virus infection; DAA; direct acting antiviral; host targeting agent; HTA; Peg IFN; peginterferon; rapid virologic response; RAV; RBV; resistance associated amino acid variant; ribavirin; RVR; sustained virologic response; SVR

Indexed keywords

ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BI 201335; BI 207127; BOCEPREVIR; DACLATASVIR; DANOPREVIR; DEB 025; DIRECT ACTING ANTIVIRAL AGENT; GS 9256; MERICITABINE; MIRAVIRSEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PROTEINASE INHIBITOR; PSI 7977; PSI 938; RIBAVIRIN; TEGOBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VX 222;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CLINICAL STUDY; DOSE RESPONSE; DRUG EFFICACY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; MATHEMATICAL MODEL; MONOTHERAPY; NOTE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRION; VIRUS REPLICATION;

EID: 84860313573     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.12.062     Document Type: Article

References (25)

1. M.W. Fried, M.L. Shiffman, K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
2. C. Hezode, N. Forestier, G. Dusheiko Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
3. P.Y. Kwo, E.J. Lawitz, J. McCone Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
4. J.G. McHutchison, G.T. Everson, S.C. Gordon Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
5. A.U. Neumann, N.P. Lam, H. Dahari Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107
6. L. Rong, H. Dahari, R.M. Ribeiro Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra32
7. C. Sarrazin, S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
8. E.J. Gane, S.K. Roberts, C.A. Stedman Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
9. S. Zeuzem, T. Asselah, P. Angus Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection Gastroenterology 141 2011 2047 2055
10. Zeuzem S, Soriano V, Asselah T, et al. Virologic response to an interferon-free regimen of BI 201335 and BI 207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the SOUND-C2 study. Presented at: 62nd Annual Meeting of the American Association of the Study of Liver Diseases; November 4-8, 2011; San Francisco, CA. LB-15.
11. Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment nave, genotype 1 HCV subjects. Presented at: 61st Annual Meeting of the American Association of the Study of Liver Diseases; October 30 to November 2, 2010; Boston, MA. LB-1.
12. Nelson DR, Gane EJ, Jacobson IM, et al. VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: ZENITH study, SVR12 interim analysis. Presented at: 62nd Annual Meeting of the American Association of the Study of Liver Diseases; November 4-8, 2011; San Francisco, CA. LB-14.
13. Lok A, Gardiner D, Lawitz E, et al. Combination therapy with BMS-790052 and BMS-650032 alone or with pegylated interferon and ribavirin (pegIFN/RBV) results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. Presented at: 61st Annual Meeting of the American Association of the Study of Liver Diseases; October 30 to November 2, 2010; Boston, MA.
14. Chayama K, Takahashi S, Kawakami Y, et al. Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders. Presented at: 62nd Annual Meeting of the American Association of the Study of Liver Diseases; November 4-8, 2011; San Francisco, CA. LB-4.
15. Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. Presented at: 2011 Annual Meeting of the European Association for the Study of the Liver; March 30 to April 3, 2011; Berlin, Germany.
16. Pharmasset initiates QUANTUM, a phase 2b interferon-free trial of PSI-7977 and PSI-938 for all HCV genotypes 2011 Pharmasset Princeton, NJ
17. T. Shimakami, C. Welsch, D. Yamane Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus Gastroenterology 140 2011 667 675
18. S. Zeuzem, P. Andreone, S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
19. Sulkowski MS, Ceasu E, Asselah T, et al. Silen-C1: Sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-nave patients with chronic genotype 1 HCV infection. Presented at: 2011 Annual Meeting of the European Association for the Study of the Liver; March 30 to April 3, 2011; Berlin, Germany.
20. Sulkowski MS, Bourliere M, Bronowicki JP, et al. Silen-C2: Sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype-1 patients with non-response to P/R. Presented at: 2011 Annual Meeting of the European Association for the Study of the Liver; March 30 to April 3, 2011; Berlin, Germany.
21. L. Coelmont, X. Hanoulle, U. Chatterji DEBO25 (Alispovir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A PLoS One 5 2010 e13687
22. Flisiak R, Pawlotsky JM, Crabbé R, et al. Once daily alisporivir (DEBO25) plus PegIFNalfa2A/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment nave patients. Presented at: 2011 Annual Meeting of the European Association for the Study of the Liver; March 30 to April 3, 2011; Berlin, Germany.
23. H. Patel, E.J. Heathcote Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3 Gut 60 2011 879
24. Janssen HL, Reesink HW, Zeuzem S, et al. A randomized, double-blind, placebo (PLB) controlled safety and antiviral proof of concept study of miravirsen (MIR), an oligonucleotide targeting miR-122, in treatment naive patients with genotype 1 (GT1) chronic HCV infection. Presented at: 62nd Annual Meeting of the American Association of the Study of Liver Diseases; November 4-8, 2011; San Francisco, CA. LB-6.
25. Zeuzem S, Arora S, Bacon BR, et al. Pegylated interferon-lambda (pegIFN-[lambda]) shows superior viral response with improved safety and tolerability versus pegIFN-[alpha]-2a in HCV patients (G1/2/3/4): EMERGE phase IIb through week 12. Presented at: 2011 Annual Meeting of the European Association for the Study of the Liver; March 30 to April 3, 2011; Berlin, Germany.